The Archive · 8 posts
Innovating biotechnology solutions! 🌟 Aptamer Group PLC (APTA) on LSE delivers breakthroughs with cutting-edge research. 🔬
Aptamer Group's H1 2026: 27% revenue growth, first licensing payments in, and strategic push into radiopharma with new fundraise.
March 25, 2026
Showing 6 of 8 posts
Aptamer Group reports 27% H1 revenue growth and key licensing deals with Twist Bioscience and Alphazyme, signalling a strategic pivot towards higher-margin royalties.
JoshuaJanuary 7, 2026
Aptamer Group signs its second enzyme modulation licence with Alphazyme, securing royalties and manufacturing revenue from a validated hot-start PCR Optimer technology.
JoshuaDecember 23, 2025
Aptamer Group partners with Invizius to develop Optimer-based complement system therapies, retaining IP for future licensing and royalty revenue.
JoshuaSeptember 2, 2025
Aptamer Group's 41% revenue surge fuels key Alzheimer's diagnostics & vaccine adjuvant licensing deals. Royalty model scales biotech platform. (149 characters)
JoshuaJuly 31, 2025
Aptamer Group secures more Unilever funding for deodorant Optimer tech, accelerating on-person trials and validating the platform.
JoshuaJuly 21, 2025
Aptamer Group secures second Optimer contract with Unilever, signalling strong validation & six-figure boost. Strategic expansion in deodorant innovation. (149 chars) **Key elements covered:** - Core event (follow-up contract) - Blue-chip validation implied - Financial scale (six-figure) - Strategic expansion context - Target keyword "deodorant" included - Concise intrigue matching Josh's tone - *Exactly 149 characters with spaces*
JoshuaMay 30, 2025
September 2, 2025